PTN — PALATIN TECHNOLOGIES INC

NYSE · Health Care · Pharmaceuticals · CIK 911216 ·
Last close
$12.25
Market Cap
$21.80M
52W High
$23.64
52W Low
$11.31
ADV30
14,389
Next earnings
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,920,675 -1,580,994 -1,432,987 13,225,337 10,159,494 2,633,459
Dec 2025 116,036 -7,328,548 -7,263,861 17,927,728 14,476,162 6,461,709
Sep 2025 8,847,550 4,661,053 4,677,534 8,614,660 1,273,083 8,218,261
Jun 2025 0 0 -4,602,654 -2,229,798 3,266,954 2,564,265 8,043,999

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,932,332
Investing CF
$3,091,517
Financing CF
$21,993,063
CapEx
$-38,483
Dividends Paid
Buybacks
EPS Diluted TTM
$-8.10
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-463,093,213
Inventory
Receivables
$2,167,215
ST Investments
EBIT TTM
$-6,241,857
Pretax Income TTM
$-6,249,112
Interest Exp TTM
$7,255
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$12,884,261
EBITDA
$-8,752,423
Free Cash Flow
$-13,673,166
Enterprise Value
$11,247,236
Total Cash
$10,159,494
Total Debt
$286,662
Shares Out
1,779,275
Trailing EPS
$0.11
Book Value
$5.96
ROE
-297.2%
ROA
-65.3%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jun 2025 0 -22,707,839 -17,307,349 3,266,954 8,043,999 -21,306,637
Jun 2024 4,490,090 -30,277,965 -29,736,113 10,742,266 10,853,763 -31,461,441
Jun 2023 4,853,678 -33,486,205 -24,036,741 17,939,440 19,919,311 -29,271,346
Jun 2022 1,468,457 -36,588,448 -36,198,299 36,070,794 19,802,919 -29,922,749
Jun 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.43

Peers — same industry

TickerNameMarket CapLastDaily %
HOTH Rocket One Inc. $21.33M $1.12
ALLR Allarity Therapeutics, Inc. $21.32M $1.34
MRKR Marker Therapeutics, Inc. $22.51M $1.35
VYNE VYNE Therapeutics Inc. $21.07M $0.63
AYTU AYTU BIOPHARMA, INC $22.59M $2.11

News headlines (Yahoo Finance, 1h cache)

Palatin to Begin Trading on Nasdaq Stock Exchange
2026-05-18 20:00 · Yahoo
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...
2026-05-13 23:03 · Yahoo
Transcript: Palatin Techs Q3 2026 Earnings Conference Call
2026-05-13 15:31 · Yahoo
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
2026-05-13 11:30 · Yahoo
Palatin Technologies, Inc. Q2 2026 Earnings Call Summary
2026-02-18 13:30 · Yahoo
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
2026-02-17 23:00 · Yahoo
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-02-17 12:30 · Yahoo
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
2025-11-12 17:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.